Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Unveiling the Role of T-Lymphocyte Clonal Hematopoiesis in Antitumor Immunity to Transform Cancer Immunotherapy

Project description

T cell mutations and anti-tumour activity

T lymphocytes vary considerably in their ability to infiltrate and attack tumours. However, the genetic factors underlying this variation are poorly understood. Emerging evidence suggests that naturally occurring mutations accumulating in T cell populations over time may actually enhance their anti-tumour activity. The ERC-funded tL-CHANCER project will investigate these mutations in cancer patients for the first time. Researchers will use large-scale genomic sequencing and advanced analytical tools to characterise how these variants influence T cell function and tumour infiltration. Overall, the project aims to unlock a new avenue for developing precision-engineered T cell therapies for solid tumours.

Objective

Cancer remains a global health crisis, with over 19 million new cases and 10 million deaths annually. Despite recent success, the efficacy of immunotherapies to treat solid tumors is still limited. T-lymphocytes, central to adaptive immunity, are key players in immunotherapy, yet their genetic heterogeneity and ability to infiltrate and respond effectively to tumors in treatment-naïve and treated patients remains poorly understood. This gap in knowledge presents a significant challenge to advancing cancer immunotherapy.

The main hypothesis of tL-CHANCER is that naturally occurring somatic mutations in T-lymphocyte expanded clones, known as T-Lymphocyte Clonal Hematopoiesis (tL-CH), enhance anti-tumor activity, offering a new approach to cancer treatment. By systematically investigating tL-CH mutations in cancer patients, I aim to uncover for the first time their impact on T-cell function, solid tumor infiltration dynamics, and anti-tumor immunity. My approach is original because it explores the uncharted landscape of tL-CH variants, rather than focusing on known T-cell mechanisms. Now is the ideal time to pursue this due to recent advancements in DNA sequencing and the growing recognition of the role of T-lymphocytes in cancer immunity. The project will leverage large-scale genomics and advanced analytical techniques to identify and characterize somatic variants in T-cells, providing insights into their functional impact on cancer immunity.

tL-CHANCER will revolutionize cancer immunotherapy by enabling the development of precision-engineered T-cell therapies based on tL-CH mutations. This research will advance our understanding of cancer evolution and create new therapeutic strategies, leading to more effective and personalized treatments for solid tumor patients. By integrating the genetic landscape of T-cells with their response to tumor-derived signals, the project will significantly impact cancer immunology and pave the way for future therapeutic innovations.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-COG

See all projects funded under this call

Host institution

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Net EU contribution
€ 1 999 750,00
Address
CALLE NAZARET 115-117
08035 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
€ 1 999 750,00

Beneficiaries (1)